Passer au contenu

/ Research

Je donne

Rechercher

Health Sciences; Life Sciences

Daniel Lévesque

Vice-doyen

Faculté de pharmacie

Pavillon Jean Coutu, room 2137-2

514 343-6339

daniel.levesque.1@umontreal.ca

Professeur titulaire

Faculté de pharmacie

Pavillon Jean Coutu, room local 3216

daniel.levesque.1@umontreal.ca

Secondary number: 514 343-7073 (Télécopieur)

Profile

education

  • 1995 — Stage postdoctoral — NeurosciencesINSERM U109
  • 1991 — Doctorat — PharmacieUniversité Laval

Teaching and supervision

Student supervision

Theses and dissertation supervision (Papyrus Institutional Repository)

Projects

Research projects

2013 - 2020

THE ROLE OF TRANSCRIPTION FACTORS NUR77 AND RETINOID X RECEPTOR (RXR) IN THE EFFECT OF ANTIPSYCHOTIC DRUG

Lead researcher : Daniel Lévesque
Co-researchers : Claude Rouillard
Funding sources: IRSC/Instituts de recherche en santé du Canada
Grant programs: PVXX5647-Subvention de fonctionnement incluant les subventions de fonctionnement programmatiques
2002 - 2020

SUBVENTION D'INFRASTRUCTURE DU FRSQ POUR LE GRSNC(GROUPE DE RECHERCHE SUR LE SYSTÈME NERVEUX CENTRAL)

Funding sources: FRQS/Fonds de recherche du Québec - Santé (FRSQ)
Grant programs: PVXXXXXX-Subvention de groupe de recherche
2017 - 2019

Neural mechanisms that sub-serve sensitization to the behavioral effects of psychostimulant drugs.

Lead researcher : Pierre-Paul Rompré
Co-researchers : Anne-Noël Samaha , Daniel Lévesque
Funding sources: IRSC/Instituts de recherche en santé du Canada
Grant programs: PVXXXXXX-(PJT) Subvention Projet
2017 - 2018

NUR77 and RXR : New Targets in Drug-Induced Dyskinesia.

Lead researcher : Sylvie Mader
Co-researchers : Daniel Lévesque
Funding sources: Ministère Économie et Innovation , MITACS Inc.
Grant programs: PVXXXXXX-Prog. soutien rech (PSR v1B): Soutien à des projets rech. (Mitacs) , PVXXXXXX-Stage Accélération Québec - MITACS
2017

NUR77 and RXR : New Targets in Drug-Induced Dyskinesia.

Lead researcher : Sylvie Mader
Co-researchers : Daniel Lévesque
2016 - 2017

Identification of Nurrl / RXR complex agonists for neuroprotection

Lead researcher : Daniel Lévesque
Co-researchers : Claude Rouillard , Tom Pfeifer
Funding sources: Weston Brain Institute
Grant programs:
2010 - 2016

NEUROTENSIN MODULATION OF LIMBIC NEUROTRANSMISSION

Lead researcher : Pierre-Paul Rompré
Co-researchers : Anne-Noël Samaha , Richard Warren , Daniel Lévesque
Funding sources: IRSC/Instituts de recherche en santé du Canada
Grant programs: PVXX5647-Subvention de fonctionnement incluant les subventions de fonctionnement programmatiques
2012 - 2015

RESEAU DE RECHERCHE EN SANTE BUCCODENTAIRE ET OSSEUSE (RSBO) GROUPE DE RECHERCHE INTERDISCIPLINAIRE SUR LA DYSKINESIE (GRID): NOUVELLES APPROCHES MOLECULAIRES ET PHARMACOLOGIQUES VERS LA PREVENTION ET LE TRAITEMENT D

Lead researcher : Frédéric Calon
Co-researchers : Guy Rouleau , Pierre J. Blanchet , Daniel Lévesque , Alain Moreau , Emmanuel Stip
Funding sources: FRQS/Fonds de recherche du Québec - Santé (FRSQ)
Grant programs: PVXXXXXX-Réseaux thématiques de recherche
2012 - 2014

NUCLEAR RECEPTORS AND DOPAMINE NEUROTRANSMISSION: A YIN-YANG RELATIONSHIP

Lead researcher : Claude Rouillard
Co-researchers : Daniel Lévesque
Funding sources: IRSC/Instituts de recherche en santé du Canada
Grant programs: PVXX5647-Subvention de fonctionnement incluant les subventions de fonctionnement programmatiques
2008 - 2014

NUCLEAR RECEPTORS AND DOPAMINE NEUROTRANSMISSION: A YIN-YANG RELATIONSHIP

Lead researcher : Daniel Lévesque
Funding sources: IRSC/Instituts de recherche en santé du Canada
Grant programs: PVXX5647-Subvention de fonctionnement incluant les subventions de fonctionnement programmatiques
2008 - 2014

IN SITU-FORMING IMPLANTS OF RIVASTIGMINE IN THE TREATMENT OF ALZHEIMER'S DISEASE

Lead researcher : Daniel Lévesque
Funding sources: IRSC/Instituts de recherche en santé du Canada
Grant programs: PVXX5647-Subvention de fonctionnement incluant les subventions de fonctionnement programmatiques
2009 - 2011

IN SITU-FORMING IMPLANTS OF RIVASTIGMINE IN THE TREATMENT OF ALZHEIMER'S DISEASE

Lead researcher : Daniel Lévesque
2008 - 2011

ANALYSES MOLECULAIRES ET CELLULAIRES DE L'EFFET DES AGENTS ANTIPSYCHOTIQUES SUR LE FACTEUR DE TRANSCRIPTION NUR77

Lead researcher : Daniel Lévesque

Outreach

Publications and presentations

Publications

Publications récentes:

Schweizer N, T Viereckel, C Smith-Anttila, K Nordenankar, E Arvisson, S Mahmoudi, A Zampera, H Warner Jonsson, J Bergquist, D Lévesque, A Konradsson-Geuken, M Andersson, S Dumas and A Wallen-Mackenzie, Reduced sugar consumption and altered size of subtalamic nucleus identify a role for Pitx2/Vglut2 co-expressing neurons in action selection, eNeuro, 3(5) e0264-16, 2016.

Fakhoury M, D Voyer, D Lévesque and PP Rompré, Effect of electrolytic lesions of the dorsal diencephalic conduction system on the distribution of Fos-like immunoreactivity induced by rewarding electrical stimulation, Neuroscience, 334: 214-225, 2016.

Voyer D, Lévesque D and PP Rompré, Repeated ventral midbrain neurotensin injections sensitize to amphetamine-induced locomotion and ERK activation: a role for NMDA receptors, Neuropharmacology, 112: 150-163, 2016.

Giner X, D Cotnoir-White, S Mader and D. Lévesque, Selective ligand activity at Nur/retinoid X receptor complexes revealed by dimer-specific bioluminescence resonance energy transfer-based sensors, FASEB J, 29: 4256-4267 2015.

Hernandez G, A Khodami-Pour, D Lévesque and PP Rompré, Reduction in ventral midbrain NMDA receptors reveals two opposite modulatory roles for glutamate on reward, Neuropsychopharmacology, 40: 1682-1691, 2015.

Rocchetti J, Isingrini E, Dal Bo G, Sagheby S, Menagaux A, Tronche F, Lévesque D, Moquin L, Gratton A, Wong TP, Rubinstein M and Giros B, Presynaptic D2 dopamine receptors control LTD expression and memory processes in the temporal hippocampus, Biol. Psychiatry, 77: 513-525, 2015.

Mahmoudi S, Lévesque D and Blanchet PJ, Upregulation of dopamine D3, but not D2, receptors correlates with tardive dyskinesia in primate model, Mov. Disorders, 29: 1125-1133, 2014. This paper was highlighted in the journal’s editorial section, Jenner P, A late appearance by the dopamine D-3 receptor, Mov. Disorders, 29: 1094-1096, 2014.

Schweizer N, Pupe S, Arvidsson E, Nordenankar K, Smith-Anttila CJA, Mahmoudi S, Andren A, Dumas S, Rajagopalan A, Lévesque D, Leao RN and Wallen-Mackenzie A, Limiting glutamatergic transmission in a Vglut2-expressing subpopulation of the subtalamic nucleus is sufficient to cause hyperlocomotion, Proc. Natl. Acad. Sci. USA, 111: 7837-7842, 2014.

Bouayad-Gervais K, Minogianis EA, Lévesque D and Samaha AN, The self administration of rapidly delivered cocaine promotes increased motivation to take the drug: contributions of prior levels of operant responding and cocaine intake, Psychopharmacology (Berlin), 231: 4241-4252, 2014.

Mahmoudi S, PJ Blanchet and D Lévesque, Haloperidol-induced Nur77 expression in non-human primate model is associated with tardive dyskinesia, Eur. J. Neurosci., 38: 2192-2198, 2013.

Minogianis EA, D Lévesque and AN Samaha, The speed of cocaine delivery determines the subsequent motivation to self-administer the drug, Neuropsychopharmacology, 38: 2644-2656, 2013.

Bédard AM, J Maheux, D Lévesque and AN Samaha, Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: implications for substance abuse in schizophrenia, Schizophrenia Bull., 39: 692-702, 2013.

Samadi P, Boutet A, Rymar V, Rewal K, Maheux J, Chakrya-Kvann J, Tomaszewski M, Beaubien F, Cloutier JF, Lévesque D and Sadikot A, Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington’s disease, Genes, Brain and Behav., 12: 108-124, 2013.

Disciplines

  • Neurosciences
  • Pharmacology

Areas of expertise

  • Axe : Découverte et validation de cibles thérapeutiques
  • Pharmacothérapie (système nerveux central)